Atezolizumab is a monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy. Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.
- Mechanism
- Curator reviewed · 2 references
Atezolizumab is a humanized IgG antibody that binds PD-L1, preventing its interaction with PD-1 and B7-1. Preventing the interaction of PD-L1 and PD-1 removes inhibition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity.
- Primary indication
- Atezolizumab has approved indications for the following conditions, with the route of administration being intravenous or subcutaneous in combination with Hyaluronidase (human recombinant), in adult patients: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following...Curator reviewed · 31 structured indications
- Formula / weight
- 145000.0 Da
- First approval
- Canada, 2017 · United States, 2016 · European Union, 2020
- Also known as
- Atezo · Tecentriq
- Code names
- MDPL3280A · MPDL-3280A · MPDL 328OA · RG-7446 · RO-5541267
- Brand names
Resolves to
What you can answer from here — as of September 05, 2026
Which drugs share a target with Atezolizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account